Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PETHEMA LAL-2019 for Ph-negative ALL
NCT04179929Recruiting
- Sponsor
- Fundación PETHEMA
- Start
- Nov 2019
- Primary completion
- Nov 2026
- Modality
- Therapeutic Enzymes, Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of vincristine, prednisone, pegaspargase, daunorubicin, methotrexate and 2 more in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Fundación PETHEMA. Primary endpoint: Overall Survival at 3 years. Started Nov 2019; status: recruiting.
02
Drugs
vincristineprednisonepegaspargasedaunorubicinmethotrexate
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NCT04179929.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04179929.